A composition comprising an anti-carcinoembryonic antigen /anti-CD3 bispecific antibody for use in treating or delaying progression of a CEA-positive cancer in an individual, wherein the treatment comprises administration of said composition in combination with a second composition, wherein the second composition comprises a human programmed death-ligand 1 (PD-L1) binding antagonist; wherein (a) the anti-CEA/anti-CD3 bispecific antibody comprises (i) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule comprising a heavy chain variable region (V H CD3) comprising a HVR-H1 sequence of SEQ ID NO:44, a HVR-H2 sequence of SEQ ID NO:45, and a HVR-H3 sequence of SEQ ID NO:46, and a light chain variable region (V L CD3) comprising a HVR-L1 sequence of SEQ ID NO:47, a HVR-L2 sequence of SEQ ID NO:48, and a HVR-L3 sequence of SEQ ID NO:49; (ii) a second and a third antigen binding domain that bind to CEA, wherein the second and third antigen binding domain are each a Fab molecule comprising a heavy chain variable region (V H CEA) comprising a HVR-H1 sequence of SEQ ID NO:38, a HVR-H2 sequence of SEQ ID NO:39, and a HVR-H3 sequence of SEQ ID NO:40, and a light chain variable region (V L CEA) comprising a HVR-L1 sequence of SEQ ID NO:41, a HVR-L2 sequence of SEQ ID NO:42, and a HVR-L3 sequence of SEQ ID NO:43; and (iii) an Fc domain composed of a first and a second subunit capable of stable association; wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the third antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain; and wherein (b) the PD-L1 binding antagonist is an antibody, comprising a heavy chain comprising a HVR-H1 sequence of SEQ ID NO:19, a HVR-H2 sequence of SEQ ID NO:20, and a HVR-H3 sequence of SEQ ID NO:21; and a light chain comprising a HVR-L1 sequence of SEQ ID NO:22, a HVR-L2 sequence of SEQ ID NO:23, and a HVR-L3 sequence of SEQ ID NO:24. (a) the anti-CEA/anti-CD3 bispecific antibody comprises (i) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule comprising a heavy chain variable region (V H CD3) comprising a HVR-H1 sequence of SEQ ID NO:44, a HVR-H2 sequence of SEQ ID NO:45, and a HVR-H3 sequence of SEQ ID NO:46, and a light chain variable region (V L CD3) comprising a HVR-L1 sequence of SEQ ID NO:47, a HVR-L2 sequence of SEQ ID NO:48, and a HVR-L3 sequence of SEQ ID NO:49; (ii) a second and a third antigen binding domain that bind to CEA, wherein the second and third antigen binding domain are each a Fab molecule comprising a heavy chain variable region (V H CEA) comprising a HVR-H1 sequence of SEQ ID NO:38, a HVR-H2 sequence of SEQ ID NO:39, and a HVR-H3 sequence of SEQ ID NO:40, and a light chain variable region (V L CEA) comprising a HVR-L1 sequence of SEQ ID NO:41, a HVR-L2 sequence of SEQ ID NO:42, and a HVR-L3 sequence of SEQ ID NO:43; and (iii) an Fc domain composed of a first and a second subunit capable of stable association; wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the third antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain; and wherein (b) the PD-L1 binding antagonist is an antibody, comprising a heavy chain comprising a HVR-H1 sequence of SEQ ID NO:19, a HVR-H2 sequence of SEQ ID NO:20, and a HVR-H3 sequence of SEQ ID NO:21; and a light chain comprising a HVR-L1 sequence of SEQ ID NO:22, a HVR-L2 sequence of SEQ ID NO:23, and a HVR-L3 sequence of SEQ ID NO:24.